[go: up one dir, main page]

NO20065651L - Spesifikke bindingsmedlemmer - Google Patents

Spesifikke bindingsmedlemmer

Info

Publication number
NO20065651L
NO20065651L NO20065651A NO20065651A NO20065651L NO 20065651 L NO20065651 L NO 20065651L NO 20065651 A NO20065651 A NO 20065651A NO 20065651 A NO20065651 A NO 20065651A NO 20065651 L NO20065651 L NO 20065651L
Authority
NO
Norway
Prior art keywords
binding members
specific binding
binding
members
binding member
Prior art date
Application number
NO20065651A
Other languages
English (en)
Inventor
Linda Gillian Durrant
Tina Parsons
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32526936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065651(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of NO20065651L publication Critical patent/NO20065651L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer et isolert, spesifikt bindingsmedlem som er i stand til å binde et sialyltetraosylkarbohydrat og direkte indusere celledød uten behovet for immuneffektorceller. Et slikt bindingsmedlem kan være et antistoff eller en del derav. Også tilveiebrakt blir anvendelsen av slike bindingsmedlemmer i medisin og nukleinsyrer som koder for slike bindingsmedlemmer.
NO20065651A 2004-05-12 2006-12-07 Spesifikke bindingsmedlemmer NO20065651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410627.4A GB0410627D0 (en) 2004-05-12 2004-05-12 Specific binding members
PCT/GB2005/001805 WO2005108430A2 (en) 2004-05-12 2005-05-11 Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Publications (1)

Publication Number Publication Date
NO20065651L true NO20065651L (no) 2007-02-06

Family

ID=32526936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065651A NO20065651L (no) 2004-05-12 2006-12-07 Spesifikke bindingsmedlemmer

Country Status (16)

Country Link
US (2) US7915387B2 (no)
EP (3) EP1745077B1 (no)
JP (2) JP4944016B2 (no)
KR (1) KR101213282B1 (no)
CN (1) CN1961004B (no)
AU (2) AU2005240837B2 (no)
BR (1) BRPI0510950A (no)
CA (1) CA2563516C (no)
ES (1) ES2400571T3 (no)
GB (1) GB0410627D0 (no)
IL (1) IL178791A (no)
MX (1) MXPA06012955A (no)
NO (1) NO20065651L (no)
NZ (3) NZ589214A (no)
WO (1) WO2005108430A2 (no)
ZA (1) ZA200609365B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP2408820A4 (en) 2009-03-16 2013-01-23 Cephalon Australia Pty Ltd HUMANIZED ANTIBODIES WITH ANTITUMOR EFFECT
JP5822841B2 (ja) * 2009-11-05 2015-11-24 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 変異型のｋｒａｓまたはｂｒａｆ遺伝子を含むがんの治療
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
EP3131929B1 (en) * 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60501277A (ja) 1983-05-09 1985-08-08 ザ　ゼネラル　エレクトリツク　カンパニ−，ピ−．エル．シ− 陰極線管表示装置
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE232902T1 (de) * 1994-03-17 2003-03-15 Merck Patent Gmbh Anti-egfr einkettige fvs und anti-egfr antikoerper
JPH09173063A (ja) 1995-12-26 1997-07-08 Cosmo Sogo Kenkyusho:Kk 抗ヒトリポタンパク質（ａ）モノクローナル抗体可変領域のＤＮＡ塩基配列およびアミノ酸配列
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CA2297692A1 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA2447139C (en) 2001-05-11 2013-11-19 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
EP2397500A1 (en) 2011-12-21
KR101213282B1 (ko) 2012-12-17
CA2563516C (en) 2013-10-01
US8343490B2 (en) 2013-01-01
EP2392598A1 (en) 2011-12-07
AU2011200487B2 (en) 2012-11-01
JP2008502324A (ja) 2008-01-31
HK1101696A1 (en) 2007-10-26
BRPI0510950A (pt) 2007-11-20
WO2005108430A2 (en) 2005-11-17
US7915387B2 (en) 2011-03-29
CN1961004A (zh) 2007-05-09
KR20070085116A (ko) 2007-08-27
CN1961004B (zh) 2012-11-07
US20080118509A1 (en) 2008-05-22
NZ593171A (en) 2012-08-31
WO2005108430A3 (en) 2006-04-27
EP1745077A2 (en) 2007-01-24
US20110212113A1 (en) 2011-09-01
CA2563516A1 (en) 2005-11-17
GB0410627D0 (en) 2004-06-16
IL178791A0 (en) 2007-03-08
IL178791A (en) 2012-07-31
NZ550738A (en) 2011-03-31
ZA200609365B (en) 2008-05-28
AU2005240837A1 (en) 2005-11-17
MXPA06012955A (es) 2007-04-25
JP2012105654A (ja) 2012-06-07
AU2011200487A1 (en) 2011-02-24
NZ589214A (en) 2012-02-24
ES2400571T3 (es) 2013-04-10
JP4944016B2 (ja) 2012-05-30
AU2005240837B2 (en) 2010-11-11
EP1745077B1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
ATE353955T1 (de) Durch zelloberflächenmoleküle induzierte makrophagenaktivierung
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
NO20065084L (no) Interferon-alfa polypeptider og konjugater
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
CY1112110T1 (el) Κυκλικο μοριο dna το οποιο διαθετει μια συμβατικη αφετηρια αντιγραφης, η διαδικασια παρασκευης του και η χρηση του στην γονιδιακη θεραπεια
DK1553832T3 (da) Præparater og fremgangsmåder til celleseparering
NO20075103L (no) Antistoffer og relaterte molekyler som bindes til 161P2F10B proteiner
NO20052363L (no) Interferon-alfa polypeptider og konjugater
WO2020120569A3 (en) Modified carrier proteins for o-linked glycosylation
NO20065651L (no) Spesifikke bindingsmedlemmer
BR112021011107A2 (pt) Anticorpos para o fator de complemento humano c2b e métodos de uso
BRPI0706532A8 (pt) mutantes de micobactéria seca2
NO20065874L (no) Antistoffer og beslektede molekyler som bindes til PSCA proteiner
DK1354054T3 (da) Polypeptider der kan binde til CD64, og som omfatter en eller flere heterologe T-celle-epitoper, samt anvendelser deraf
ATE389397T1 (de) Adjuvante zusammensetzungen
ATE555124T1 (de) Nukleinsäuren und entsprechende proteine 58p1d12 zum nachweis von krebs
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
NO20062015L (no) Anti-NIK-antistoffer og anvendelser derav
NO20052714L (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
EP1789452A4 (en) RELAXIN-CHIMERO POLYPEPTIDES AND THEIR PREPARATION AND APPLICATION
NO20075592L (no) Antistoffer og beslektede molekyler som bindes til PSCA Proteiner

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, AU

FC2A Withdrawal, rejection or dismissal of laid open patent application